Q&A: FDA update to biosimilar approval process may reduce time, cost of development

An FDA draft guidance nixing the requirement for biosimilar manufacturers to conduct comparative efficacy studies may prove “consequential” in reducing the time and cost of bringing biosimilars to market, according to an expert.In the last quarter of 2025, the FDA released a draft guidance on biosimilar development stipulating that comparative efficacy studies are no longer required